Daniel Fisch

Daniel Fisch

@danielhfisch.bsky.social

Group Leader at the Gulbenkian Institute for Molecular Medicine (GIMM) Innate Immunology, Macrophages & Toll-Like Receptors πŸ”¬πŸ‘¨β€πŸ”¬

332 followers656 following47 posts

Thank you for inviting me to join @gimminstitute.bsky.social! Exciting times ahead!

GIMM Institute@gimminstitute.bsky.social

Welcome to GIMM, @danielhfisch.bsky.social! πŸ’œ As Group Leader in Innate Immunity, Daniel studies how our immune system detects and responds to infections. πŸ”¬ He looks forward to building his team and collaborating with GIMM’s scientific community.

After Germany, the UK, France and the US, it feels wonderful to build my scientific home back in Europe. πŸ§ͺπŸ‡΅πŸ‡Ή Now the exciting part begins...building a team and chasing big questions together. Can't wait for the discoveries ahead!

View full thread

I want to thank all my colleagues from the Kagan lab for making this work possible and especially @jkagan1.bsky.social for his support of my postdoc training and mentorship for the past 5 years! Thanks to all funders supporting this work! (NIH, HFSP, EMBO, HRIA King Trust, CRI Irvington).

View full thread

If long-lived myddosomes sustain inflammation, disrupting them should stop it. Conversely, MyD88 oligomerization inhibitors (MPP, TSI-13-57) dissolved already-formed myddosomes in cells. We detected for the first time native myddosomes in mice, which could be shut down by the same inhibitors.

View full thread

We could separate the role of TRAM in the TRIF-arm from its role in the MyD88-arm of TLR signaling based on its localization. Forcing TRAM to the plasma membrane restores myddosome release but abolishes IFN. Endosome-restricted TRAM does the opposite.

We then reconstituted the release mechanism in vitro with three TIR domains. We found that TIRAP restrains MyD88 self-assembly and TRAM relieves that restraint. The purified domains are sufficient to reproduce the behavior seen in cells.

View full thread

Across bacterial infections, TRAM was required for IL-6 but not TNFΞ± production. In infected cells MyD88 again remained at the plasma membrane when TRAM was absent.

For releasing myddosomes TRAM acts alongside TIRAP in PI(4,5)P2-rich plasma-membrane microdomains. TRAM mutants, chimeras and CRISPR-Activation showed that the local TIRAP:TRAM ratio, rather than the abundance of either protein, determines whether myddosomes are released.

View full thread

The release is what makes TLR signaling last. While WT macrophages sustain NF-ΞΊB for hours, TRAM-deficient cells produce a single peak and then terminate signaling early.

This reflects in transcription: Primary response genes are induced without TRAM, but secondary response genes (e.g. IL-6, IL-12) are not. By RNA-seq, TRAM-deficient macrophages return to baseline by 6 h while WT cells remain activated.

View full thread

Without TRAM, MyD88 does not move. Proto-myddosomes still nucleate at the plasma membrane but are never released, and no cytosolic myddosomes form. Other adaptor knockouts behaved as expected; Ξ”TRAM was unique in that myddosome assembly starts but maturation fails.

Using minute-by-minute co-IPs we found that MyD88 first binds TLR:TIRAP (proto-myddosome), TRAM then releases MyD88 so it can recruit IRAK2/4 and TRAF6 (mature myddosome). Without TRAM, MyD88 stays bound to TLR:TIRAP for hours.

We began the study by exploring which cells actually respond to TLR-ligands? Using a side-scatter-based sort we separated macrophages into myddosome-containing responders and myddosome-free bystanders. Only responders switch on the TLR gene program.

To find what builds a myddosome, we performed a genome-wide CRISPR screen, sorting for cells with no myddosomes and no NF-ΞΊB activity. We obtained one very unexpected hit: TRAM (Ticam2), the adaptor long exclusively assigned to the MyD88-independent TRIF pathway.

Daniel Fisch reposted

Congrats to Samira Schiefer on her new paper in Science Advances! We analysed 70 natural human IFNB1 variants & found both loss- & gain-of-function IFNΞ² proteins, revealing unexpected diversity in antiviral immunity. Great effort with Dave Jones & Florence Kwaschik! www.science.org/doi/10.1126/...

science.orgFunctional diversity of natural human IFNB1 variants in innate immunityHuman interferon-Ξ² (IFN-Ξ²), a type I IFN, is critical for effective innate immunity and is also an approved disease-modifying therapeutic. While genetic variations in several components of the type I ...

Daniel Fisch reposted

Exciting news! Our @erc.europa.eu StG project ARCHAEAOLOGY got funded πŸŽ‰ We’ll combine cryoET/EM, ExM & spatial omics to explore the subcellular organization of Asgard archaea. Job ads coming soon! 🦠 ❄️ πŸ”¬ #TeamTomo #ArchaeaSky #MicroSky

EMBL@embl.org

Congratulations to @florianwollweber.bsky.social, the recently appointed Group Leader at EMBL Grenoble, who received an ERC Starting Grant worth approximately €2 million to investigate the origins of eukaryotic cell complexity. bit.ly/4gNwEBk

Daniel Fisch reposted

The lab is a mysterious place--where some people have "magic hands," and some experiments just won't work. Here's my story about the unspoken knowledge of science, and the struggle to share it. Gift link: nyti.ms/3UccF7Z

Daniel Fisch reposted

Graphing and statistically analyzing data is challenging without coding expertise. This Community Page by @avishenoy.bsky.social introduces grafify online, a free, browser app for generating publication-quality graphs and performing statistical tests and comparisons. πŸ§ͺ #AcademicSky plos.io/3RpUg6E

Daniel Fisch reposted

Apply until May 3rd, 2026 Join GIMM for a PhD in Biology & Biomedicine (Jan 2027). 🧬 We advance research addressing complex biological questions while providing the foundational and professional skills required for multiple career paths. πŸ”— gimm.pt/education-an...

Daniel Fisch reposted

Daniel Fisch reposted

Europe's MSCA postdoctoral fellowships are now attracting many researchers who would have gone to the US. So the payline has dropped below 10% (~1,600 fellowships to 17k applicants). Super tough situation. One more reason to double the next Horizon budget, as proposed by the EU Commission.

Tom Emery@drtomemery.bsky.social

Applications for MCSA are up 64%! 50% now come from outside the EU. Trump effect? The European Research market just got a hell of a lot more crowded. EU should turn on the tap marie-sklodowska-curie-actions.ec.europa.eu/news/msca-po...

Daniel Fisch reposted

#InflammasomePower! πŸ’₯New paper alertπŸ’₯ How is NLPR3 primed & activated in chronic non-communicable inflammatory diseases? With @oceanedufies.bsky.social &co we show that chronic exposure to oxPAPC drives NRF2 activation that primes & activates NLRP3 sustaining #atherosclerosis in mice & humans! πŸ‘‡πŸ‘‡πŸ‘‡

biorxiv.orgChronic sensing of host-derived lipids is an all-in-one signal that primes and activates NLRP3.Activation of the NLRP3 inflammasome leads to the production of bioactive interleukin (IL)-1Ξ² fostering atherosclerosis. The current dogma is that NLRP3 must be first primed by microbial stimuli, know...

Daniel Fisch reposted

Daniel Fisch reposted

Daniel Fisch reposted

Daniel Fisch reposted

So excited that this study is now online! It's been a pleasure to work with BioAge Labs and our collaborators on this story. We characterise a new class of #NLRP3 inhibitors with translational potential for so many inflammatory diseases.

#NLRP3 is a target for antiinflammatory therapies & can be inhibited by the tool compound MCC950. Wilhelmsen, @colllab.bsky.social et al characterize new small-molecule inhibitors, BAL-0028 & BAL-0598, that have a distinct mechanism of action & binding site. rupress.org/jem/article/... #Inflammasome

Daniel Fisch reposted

Daniel Fisch reposted

Daniel Fisch reposted

🚨Join us! We're soon opening 3 postdoctoral positions in #AIDrivenBiology. Seeking biologists (especially microbiology and infection biology), computer scientists, and microscopy developers. Ideal candidates are those eager to use or develop next-gen tech for cell biology. Get in touch (DM/email)